Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Vagina | 10 | 2020 | 327 | 2.94 | Why? |
| Vaginosis, Bacterial | 3 | 2018 | 51 | 1.52 | Why? |
| Dysbiosis | 4 | 2020 | 685 | 1.50 | Why? |
| Sexually Transmitted Diseases | 4 | 2019 | 694 | 1.15 | Why? |
| Microbiota | 4 | 2017 | 1240 | 1.00 | Why? |
| Contraceptive Devices, Female | 4 | 2018 | 11 | 0.75 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2020 | 114 | 0.74 | Why? |
| HIV Seropositivity | 1 | 2020 | 320 | 0.67 | Why? |
| Streptococcus agalactiae | 1 | 2017 | 194 | 0.64 | Why? |
| Urinary Tract Infections | 1 | 2019 | 534 | 0.50 | Why? |
| HIV Infections | 9 | 2018 | 11620 | 0.49 | Why? |
| Rwanda | 6 | 2019 | 270 | 0.46 | Why? |
| HIV-2 | 1 | 2011 | 92 | 0.44 | Why? |
| Uterine Cervical Neoplasms | 1 | 2020 | 842 | 0.44 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.44 | Why? |
| Papillomavirus Infections | 1 | 2020 | 861 | 0.43 | Why? |
| Lactobacillus | 3 | 2018 | 92 | 0.41 | Why? |
| Herpes Genitalis | 3 | 2019 | 90 | 0.38 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.35 | Why? |
| Sex Workers | 1 | 2011 | 348 | 0.32 | Why? |
| HIV-1 | 3 | 2013 | 3365 | 0.31 | Why? |
| Point-of-Care Systems | 1 | 2019 | 2955 | 0.29 | Why? |
| Patient Compliance | 1 | 2014 | 1468 | 0.26 | Why? |
| Medroxyprogesterone Acetate | 1 | 2019 | 10 | 0.20 | Why? |
| Trichomonas Infections | 1 | 2019 | 24 | 0.20 | Why? |
| Vaginal Smears | 1 | 2020 | 89 | 0.20 | Why? |
| Herpesvirus 2, Human | 2 | 2011 | 137 | 0.19 | Why? |
| Ethinyl Estradiol | 1 | 2018 | 3 | 0.19 | Why? |
| Contraceptives, Oral, Hormonal | 1 | 2019 | 42 | 0.19 | Why? |
| Hygiene | 1 | 2006 | 987 | 0.19 | Why? |
| Desogestrel | 1 | 2018 | 10 | 0.19 | Why? |
| Proteus | 1 | 2017 | 5 | 0.18 | Why? |
| Absenteeism | 1 | 2020 | 287 | 0.18 | Why? |
| Contraceptive Devices | 1 | 2017 | 9 | 0.18 | Why? |
| Contraceptive Agents | 1 | 2018 | 62 | 0.18 | Why? |
| Netherlands | 4 | 2021 | 3533 | 0.17 | Why? |
| Bifidobacterium | 1 | 2017 | 52 | 0.17 | Why? |
| Corynebacterium | 1 | 2017 | 47 | 0.17 | Why? |
| Streptococcus | 1 | 2017 | 76 | 0.17 | Why? |
| Zimbabwe | 2 | 2009 | 198 | 0.17 | Why? |
| Staphylococcus | 1 | 2017 | 77 | 0.16 | Why? |
| Research Report | 1 | 2021 | 376 | 0.16 | Why? |
| Ultrasonography | 3 | 2021 | 4409 | 0.15 | Why? |
| Radiography, Thoracic | 3 | 2021 | 5486 | 0.15 | Why? |
| Papillomaviridae | 1 | 2020 | 404 | 0.15 | Why? |
| Vaginal Creams, Foams, and Jellies | 1 | 2014 | 5 | 0.14 | Why? |
| Motivation | 2 | 2017 | 1640 | 0.14 | Why? |
| Administration, Intravaginal | 1 | 2014 | 38 | 0.14 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.14 | Why? |
| Streptococcal Infections | 1 | 2017 | 255 | 0.14 | Why? |
| Biofilms | 1 | 2017 | 304 | 0.14 | Why? |
| Uganda | 2 | 2009 | 1057 | 0.13 | Why? |
| RNA, Ribosomal, 16S | 1 | 2017 | 793 | 0.13 | Why? |
| Wearable Electronic Devices | 1 | 2021 | 694 | 0.13 | Why? |
| Mozambique | 1 | 2014 | 205 | 0.13 | Why? |
| Enterobacteriaceae | 1 | 2017 | 395 | 0.13 | Why? |
| Female | 20 | 2021 | 380317 | 0.12 | Why? |
| Safe Sex | 1 | 2011 | 135 | 0.11 | Why? |
| Community Participation | 1 | 2017 | 605 | 0.10 | Why? |
| Condoms | 1 | 2011 | 235 | 0.10 | Why? |
| Pregnancy Complications, Infectious | 2 | 2017 | 11559 | 0.10 | Why? |
| BCG Vaccine | 1 | 2020 | 1137 | 0.10 | Why? |
| Informed Consent | 1 | 2017 | 890 | 0.10 | Why? |
| Adult | 16 | 2021 | 244371 | 0.10 | Why? |
| South Africa | 1 | 2020 | 3326 | 0.10 | Why? |
| Sexual Partners | 1 | 2014 | 612 | 0.09 | Why? |
| Biomass | 2 | 2018 | 80 | 0.09 | Why? |
| Early Detection of Cancer | 1 | 2020 | 1956 | 0.09 | Why? |
| Attitude | 1 | 2017 | 1481 | 0.08 | Why? |
| Sexual Behavior | 2 | 2014 | 1322 | 0.08 | Why? |
| Adolescent | 8 | 2021 | 86841 | 0.08 | Why? |
| Humans | 27 | 2021 | 930598 | 0.08 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.08 | Why? |
| Pregnancy | 4 | 2021 | 23879 | 0.08 | Why? |
| Primary Prevention | 1 | 2013 | 778 | 0.08 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.08 | Why? |
| Sex Work | 1 | 2006 | 96 | 0.08 | Why? |
| Tomography, X-Ray Computed | 3 | 2021 | 25144 | 0.07 | Why? |
| Bias | 2 | 2021 | 1109 | 0.07 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.07 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.07 | Why? |
| Research Design | 1 | 2021 | 5830 | 0.07 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.07 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Kenya | 1 | 2006 | 887 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.06 | Why? |
| Risk | 2 | 2019 | 5288 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Anti-HIV Agents | 1 | 2013 | 2209 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Confidence Intervals | 1 | 2021 | 744 | 0.04 | Why? |
| Gardnerella vaginalis | 1 | 2017 | 11 | 0.04 | Why? |
| Contraception Behavior | 1 | 2018 | 60 | 0.04 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.04 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2021 | 867 | 0.04 | Why? |
| Holidays | 1 | 2021 | 311 | 0.04 | Why? |
| Reference Standards | 1 | 2021 | 1163 | 0.04 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.04 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.04 | Why? |
| Microscopy, Electron, Scanning | 1 | 2017 | 221 | 0.04 | Why? |
| Contraception | 1 | 2018 | 291 | 0.03 | Why? |
| Research Subjects | 1 | 2017 | 178 | 0.03 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.03 | Why? |
| Focus Groups | 1 | 2018 | 811 | 0.03 | Why? |
| Diagnostic Errors | 1 | 2020 | 865 | 0.03 | Why? |
| Middle Aged | 5 | 2021 | 270681 | 0.03 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Organophosphonates | 1 | 2013 | 85 | 0.03 | Why? |
| Deoxycytidine | 1 | 2013 | 116 | 0.03 | Why? |
| Emtricitabine | 1 | 2013 | 202 | 0.03 | Why? |
| Zambia | 1 | 2013 | 401 | 0.03 | Why? |
| Public Health Practice | 1 | 2020 | 945 | 0.03 | Why? |
| Reproductive Health | 1 | 2017 | 473 | 0.03 | Why? |
| Coinfection | 1 | 2011 | 6820 | 0.03 | Why? |
| Mass Screening | 1 | 2011 | 8005 | 0.03 | Why? |
| Child | 4 | 2021 | 70012 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Risk Factors | 2 | 2011 | 71621 | 0.03 | Why? |
| Adenine | 1 | 2013 | 463 | 0.03 | Why? |
| Models, Biological | 2 | 2021 | 4907 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.02 | Why? |
| Tenofovir | 1 | 2013 | 449 | 0.02 | Why? |
| Basic Reproduction Number | 1 | 2021 | 2676 | 0.02 | Why? |
| Interviews as Topic | 1 | 2018 | 1952 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Africa | 1 | 2017 | 2986 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Lung | 3 | 2021 | 31049 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Aged | 4 | 2021 | 215776 | 0.02 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.02 | Why? |
| Incidence | 1 | 2009 | 25622 | 0.02 | Why? |
| Male | 4 | 2021 | 367725 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.02 | Why? |
| Cohort Studies | 1 | 2009 | 36005 | 0.02 | Why? |
| Schools | 1 | 2021 | 4187 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Qualitative Research | 1 | 2017 | 4337 | 0.02 | Why? |
| Mobile Applications | 1 | 2020 | 3032 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2013 | 2259 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.01 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.01 | Why? |
| Rural Population | 1 | 2013 | 2408 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
van de Wijgert's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(166)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(95)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_